{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=optimized+background+therapy", "query": { "intervention": "optimized background therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=optimized+background+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T23:49:40.078Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00197197", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-07", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2011-03-29", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 11, "location_summary": "Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197197" }, { "nct_id": "NCT00488059", "title": "A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" }, { "name": "Optimized background ARV", "type": "DRUG" }, { "name": "Integrase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-06", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2011-07-22", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 41, "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488059" }, { "nct_id": "NCT00089492", "title": "A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Optimized Background ARVs", "type": "DRUG" }, { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 64, "start_date": "2004-07", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 21, "location_summary": "Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089492" }, { "nct_id": "NCT00665561", "title": "Prospective Observational Epidemiologic Study of Maraviroc's Safety", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Maraviroc along with an optimized background antiretroviral drug regimen", "type": "DRUG" }, { "name": "Optimized background antiretroviral drug regimen without maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2500, "start_date": "2008-03-31", "completion_date": "2019-02-14", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 145, "location_summary": "Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00665561" }, { "nct_id": "NCT05582694", "title": "A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multi-Drug Resistant Hiv-1 Infection", "HIV-1 Infection" ], "interventions": [ { "name": "UB-421", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-07-10", "completion_date": "2025-07-10", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05582694" }, { "nct_id": "NCT00515827", "title": "Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir (MK-0518)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2007-11", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00515827" }, { "nct_id": "NCT00089700", "title": "TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "TNX-355", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanox", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Altamonte Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089700" }, { "nct_id": "NCT00197145", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-07-21", "completion_date": "2007-09-11", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Laguna Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197145" }, { "nct_id": "NCT02475629", "title": "Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "ibalizumab", "type": "BIOLOGICAL" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TaiMed Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-08", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 27, "location_summary": "Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02475629" }, { "nct_id": "NCT00056641", "title": "Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "tipranavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "saquinavir", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "lopinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2003-02-18", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-09-11T23:49:40.078Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056641" } ] }